Streetwise Interviews



Why the Canadian Marijuana Sector Is the Next Big Thing and Why Emblem Is Our Top Pick
Source: Gecko Research for Streetwise Reports  (12/8/16)
Gecko Research discusses the bull market for marijuana, the road to legalization in Canada and why Emblem Corp., which begins trading on the TSX.V on Dec. 12 under the symbol EMC, is their top pick. More >


Reliq Health Technologies Pilots Remote Patient Monitoring Program
Source: The Life Sciences Report  (12/7/16)
Reliq Health Technologies is initiating a trial of its remote patient monitoring system with The Feldman Institute in Louisiana, the fourth program for the company's innovative technology. More >


Can Biotech's Trump Bump Last?
Source: The Life Sciences Report  (12/2/16)
In the weeks since Donald Trump's presidential election victory, the stock markets have ridden a wave into positive—and in the case of the Dow, record-breaking—territory. The so-called Trump Bump also sent biotech indices, flaccid for much of the year, up as much as 15%. With the election now nearly a month old, and hot-button issues such as drug pricing still in the press, industry watchers have begun to weigh in on what might happen in the biotech and pharma markets when Trump takes office. More >


Agreement Launches RXi Pharmaceuticals into Dynamic Immuno-Oncology Arena
Source: The Life Sciences Report  (11/14/16)
By securing an exclusive option to acquire MirImmune Inc., RXi Pharmaceuticals has expanded its reach into the "high-value" field of immuno-oncology, a move that has energized the company and prompted a pair of analysts to express optimism about RXi's future. More >


Len Yaffe

Why the Election Is Not as Relevant to Drug Stocks as You Might Believe
Source: Dr. Len Yaffe for The Life Sciences Report  (11/2/16)
Due to drug pricing controversies, there has been much concern about how the outcome of the upcoming election will affect pharmaceutical stocks. Dr. Len Yaffe of Stoc*Doc Partners sheds light on the issues in this analysis of drug price negotiation policy, and focuses in on one California ballot proposition that aims to rein in costs. More >


Len Yaffe

Exploring Solutions to Healthcare's Spending Crisis
Source: Dr. Len Yaffe for The Life Sciences Report  (10/19/16)
Rising healthcare costs continue to preoccupy providers, patients, politicians and investors. Some cost increases stem from inefficiencies in the medical system, some from social and demographic trends, and others are a function of profit motives on the part of insurers and a few drug companies. In this article for The Life Sciences Report, Dr. Len Yaffe of Stoc*Doc Partners reviews the issues and proposes some cures. More >


Analysts Keep Focus on DURECT's DUR-928
Source: The Life Sciences Report  (10/6/16)
The FDA's recent Complete Response Letter for Remoxy, which is licensed by DURECT to Pain Therapeutics, has not changed the view of several analysts who follow DURECT. They are focused on DUR-928 for NASH and impaired kidney function, indications that are of great interest to Big Pharma. More >


Anthony Vendetti

Viveve's Treatment for Improving Women's Sexual Function May Leapfrog the Competition
Source: The Life Sciences Report  (10/5/16)
Private-pay aesthetic procedures constitute a trend in medical devices, according to Anthony Vendetti, Director of Research at Maxim Group. These nonreimbursable types of procedures have seen rapid growth in the past decade. In this interview with The Life Sciences Report, Vendetti discusses Viveve Medical, which is attempting to leapfrog the competition to get FDA approval to use its patented radiofrequency technology to improve women's sexual function. More >


Bob Moriarty

Imagin, a Better Way to Detect Bladder Cancer
Source: Bob Moriarty for The Life Sciences Report  (9/20/16)
Bob Moriarty profiles Imagin Medical, a company that has developed a new way of detecting bladder cancer through endoscopes. More >


Regeneus Secures Government Funding for R&D
Source: The Life Sciences Report  (9/14/16)
The Australian government has bolstered Regeneus, a regenerative medicine company targeting cancer, osteoarthritis and other musculoskeletal conditions, with $2.73 million in funding. More >


Three Shots on Goal in Q4/16 for DURECT Corp.
Source: The Life Sciences Report  (9/8/16)
With a trifecta of share-moving milestones anticipated in Q4/16, including possible FDA approval of abuse-resistant opioid Remoxy, Laidlaw & Co. Analyst Jim Molloy sees blue sky ahead for DURECT Corp. More >


Soligenix's Diversified Pipeline Advances on All Fronts
Source: The Life Sciences Report  (8/31/16)
The late-stage biopharmaceutical company Soligenix has had a string of good news. Revenue is up, the FDA awarded orphan status to a key drug, and BARDA and NIAID have granted the firm additional funding, plus the company is developing vaccines against Ebola and ricin, and has several other ongoing trials. Analyst Grant Zeng of Zacks Investment Research assesses the landscape. More >


Inovio Expands Ebola Vaccine Trial
Source: The Life Sciences Report  (8/24/16)
Inovio Pharmaceuticals Inc. (INO:NASDAQ) has expanded the Phase 1 trial of its Ebola vaccine to include an additional 125 healthy subjects. This, according to Maxim Group analyst Jason Kolbert, will help the company determine an "optimal" strategy for intradermal (skin) vaccination. More >


Radioimmunotherapy 2.0: Actinium Sets Eyes on Bone Marrow Transplant and AML with Later-Stage Programs
Source: The Life Sciences Report  (8/17/16)
Radioimmunotherapy is experiencing a renaissance, and Actinium Pharmaceuticals Inc. is in position to benefit, according to company executive chairman Sandesh Seth. With two assets targeting treatment of AML in older adults in clinical trials, and a platform primed to "nuke cancer," the company has a number of milestones in its near future that investors should be watching. More >


Stuart Roberts

The ASX: Investing in an Emerging Biotech Frontier
Source: Stuart Roberts for The Life Sciences Report  (8/10/16)
Concerned about investing in the life sciences in the United States, where markets have slumped in 2016 and the presidential election furthers volatility? NDF Research Founder Stuart Roberts makes an argument for taking a look at investment opportunities Down Under. More >


Resverlogix Seeks Orphan Status for Lead Drug Candidate
Source: The Life Sciences Report  (8/3/16)
With its lead drug candidate apabetalone already in Phase 3 targeting major adverse cardiac events, Resverlogix has expanded its scope by initiating a Phase 1 study of the small molecule to further investigate its potential applications. More >


Nobilis Moves Forward with New President and New Canaccord Coverage
Source: The Life Sciences Report  (7/20/16)
Under the guidance of newly appointed president Kenneth Efird, Nobilis Health Corp. plans to continue to roll out new products and optimize its marketing strategy. More >


DURECT's Abuse-Deterrent Opioid Poised for FDA Approval
Source: Tracy Salcedo of The Life Sciences Report  (7/13/16)
Oxycodone is a powerful and lucrative painkiller, but one with serious downsides. Dependency on the opioid has become a major issue medically, politically and, most profoundly, for the patients whose addictions have become debilitating or fatal. DURECT Corp.'s Remoxy, an abuse-deterrent formulation of oxycodone, has an FDA approval date of Sept. 25, 2016, and may provide a safer alternative. More >


How Sick Will Brexit Make Biotech and Pharma?
Source: Tracy Salcedo of The Life Sciences Report  (6/29/16)
In tandem with the broader markets, the biotech indices reeled on the news of Britain's vote to exit the European Union. Given the uncertainty and dire economic forecasts, The Life Sciences Report has reviewed commentary from sector experts and biotech publications to help investors understand what Brexit might mean for the industry. More >


Jason McCarthy

Partnerships Propel Stellar Biotechnologies' Vaccine Technology
Source: Tracy Salcedo of The Life Sciences Report  (6/22/16)
Maxim analyst Jason McCarthy sees nothing but blue sky for Stellar Biotechnologies Inc., even though its product originated in the deep blue sea. With blockbuster indications like cancer, lupus and Alzheimer's disease being targeted by partners, and a manufacturing process sure to satisfy regulators, McCarthy lays out a value proposition for Stellar's KLH that investors should not ignore. More >


Soligenix Develops Defenses Against Bioterrorism
Source: Staff of The Life Sciences Report  (6/15/16)
Maxim Group biotech analyst Jason Kolbert notes "steady progress" is being made by Soligenix Inc., a small-cap biotech with programs addressing bioterrorism threats and a devastating side effect of cancer treatment, in his Q1/16 update on the company. More >


George Mack

Investment in Cell and Gene Therapies Ramps Up
Source: George S. Mack of The Life Sciences Report  (6/8/16)
After decades of disappointment, cell therapies and gene therapies are finally seeing light at the end of the tunnel. Investors, investigators, clinicians, and patients with serious unmet needs are watching pivotal trials move into the home stretch. Yes. . .pivotal data are actually on the way. More >


Punit Dhillon

OncoSec Delivers Cancer Therapy Straight to the Tumor
Source: Special to The Life Sciences Report  (6/1/16)
Cancer patients often receive multiple rounds of chemotherapy, with new drugs incorporated into treatment programs as tumors develop resistance. OncoSec Medical Incorporated's Punit Dhillon describes how his company is challenging that paradigm with a proprietary platform that delivers therapeutic agents directly to the tumor, while also laying a foundation for expanded use of combination immunotherapies at the forefront of cancer treatment. More >


Kolin Ozonian

How Nobilis Health Will Break Out of the Healthcare Payment Mold
Source: George S. Mack of The Life Sciences Report   (5/25/16)
Managing both acquisitions and internal growth at the same time is difficult for most small companies, akin to drinking water and singing at the same time. Not so for Nobilis Health Corp., which is orchestrating the flow of new patients to its ambulatory surgical centers while it adds an ensemble of new clinics, resulting in harmonious revenue. The conductor is merger-and-acquisition specialist Kolin Ozonian, who brings years of business development experience in large-cap healthcare to this small-cap enterprise. In this interview with The Life Sciences Report, Ozonian discusses his company's newest technology and talks about how Nobilis will achieve critical mass. More >


Charles Duncan

With Potential Vaccines for Cancer, Ebola and Zika, Inovio Could Have an Explosive 2016
Source: The Life Sciences Report  (5/18/16)
Recent news from Inovio Pharmaceuticals Inc., a small-cap biotech developing immunotherapeutic vaccines that target cancer and infectious diseases like news-making viruses Ebola and Zika, has prompted Piper Jaffray analyst Charles Duncan to reiterate his thesis for investment in the company. More >


Showing Results: 1 to 25 of 337 Next